Questions 70 – 71: Did engraftment syndrome occur?

Engraftment syndrome typically occurs during neutrophil recovery post-HCT and is characterized by capillary leak syndrome, non-infectious fever, erythrodermatous skin rash, and non-cardiogenic pulmonary edema. Engraftment syndrome is usually seen following autologous transplants but can occur after allogeneic transplants. It is associated with increased transplant mortality, generally from pulmonary and associated multi-organ failure. Corticosteroid therapy is often an effective treatment for engraftment syndrome, mainly for the treatment of pulmonary symptoms.

Indicate whether the recipient developed engraftment syndrome.

If the recipient developed engraftment syndrome during the reporting period, report Yes and indicate the date of diagnosis. If the recipient did not develop engraft syndrome, report No and continue with question 81.

For more information regarding reporting partial or unknown dates, see General Instructions, General Guidelines for Completing Forms.

Questions 72 – 73: Specify the symptoms of engraftment syndrome (check all that apply)

Specify the engraftment syndrome symptoms the recipient developed in the reporting period. Check all that apply. If Other symptom is selected, specify the symptom present.

Questions 74 – 77: Was a biopsy performed?

Indicate Yes or No if a biopsy was performed to evaluate engraftment syndrome. If Yes, specify the site(s) and indicate whether documentation (pathology report) was attached to the form in FormsNet3 or otherwise submitted to the CIBTMR. If Other site is selected, specify the biopsy site.

For further instructions on how to attach documents in FormsNet3, refer to the training guide.

If no biopsies were done to evaluate for engraftment syndrome, report No and continue with question 78.

Questions 78 – 79: Specify therapy given for engraftment syndrome (check all that apply)

Specify any therapy given for engraftment syndrome. If Other therapy is selected, specify the treatment(s) administered. If therapy was not given, select None and continue with question 80.

Question 80: Did engraftment syndrome resolve?

Indicate whether engraftment syndrome resolved during the reporting period. If engraftment syndrome was still present on the date of contact, report No.

Section Updates:

Question Number Date of Change Add/Remove/Modify Description Reasoning (If applicable)
Q70 – 78 5/18/2022 Add Combined Follow-Up blue instruction box added: In scenarios where a cellular therapy was given after an HCT and this form is now being completed based on the subsequent cellular therapy date, these questions do not apply and are disabled. Added for clarification
Last modified: May 18, 2022

Need more help with this?
Don’t hesitate to contact us here.

Was this helpful?

Yes No
You indicated this topic was not helpful to you ...
Could you please leave a comment telling us why? Thank you!
Thanks for your feedback.